Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-0646
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab ; day:2 ; month:5 ; year:2017 ; pages:1-3
Investigational new drugs ; (2.5.2017), 1-3
- Creator
-
Mamesaya, Nobuaki
- Contributor
-
Kenmotsu, Hirotsugu
Takahashi, Toshiaki
SpringerLink (Online service)
- DOI
-
10.1007/s10637-017-0471-y
- URN
-
urn:nbn:de:1111-201705134952
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mamesaya, Nobuaki
- Kenmotsu, Hirotsugu
- Takahashi, Toshiaki
- SpringerLink (Online service)
Other Objects (12)
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis